Dodecafluoropentane emulsion not checked
NuvOx LLC · NanO2TM · NanO2
FollowEvery change as it happens, and a Monday email
Trials
2 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Glioblastoma Multiforme, Mild Respiratory Distress
- Main trialPhase 2
- “This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.”In the company’s words, NCT03862430 on ClinicalTrials.gov
- Other names
- NanO2TM · dodecafluoropentane · NanO2
Other drugs for Glioblastoma Multiforme
- 131I-IPATelix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- SafusidenibNuvation Bio · Phase 3
- Cerebraca waferEverfront Biotech Co., Ltd. · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- LAM561Laminar Pharmaceuticals · Phase 2/3
- VebreltinibBeijing Pearl Biotechnology Limited Liability Company · Phase 2/3
Coming up2
- DecPhase 1 trial completes · ClinicalTrials.gov
- 30 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 30 Jun 2027 | A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM | |
| Phase 1Recruiting | Dec 2026 | A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress | |
| Phase 2/3Unknown | 1 Apr 2025 | NanO2 for Large Vessel Occlusion Stroke |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026